Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment
October 02, 2024 at 08:32 AM EDT
Recursion said it was able to use its AI-enabled drug discovery platform to identify a novel target and move all the way to gaining IND approval in less than 18 months.